SMMT - Company ID 0001599298
The table below shows Summit Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0.00 | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $132.62M | - | - | $51.27M | - | - |
| SG&A |
Summit Therapeutics Inc. reported annual revenue of $0.00 for fiscal year 2024. Over the 8 fiscal years shown, annual revenue declined from $16.10M (FY 2018) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $62.59M |
| $103.11M |
| $360.42M |
| $15.59M |
| $20.65M |
| $13.81M |
| Operating income | - | - | - | - | -$58.38M | -$59.62M |
| Income tax | - | - | - | - | - | - |
| Net income | -$189.42M | -$231.79M | -$565.71M | -$62.91M | -$56.25M | -$60.38M |
| EPS (diluted) | -$0.24 | -$0.31 | -$0.76 | -$0.09 | -$0.08 | -$0.09 |